Form 8-K - Current report:
SEC Accession No. 0001493152-22-023285
Filing Date
2022-08-17
Accepted
2022-08-17 10:44:53
Documents
13
Period of Report
2022-08-15
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 33974
  Complete submission text file 0001493152-22-023285.txt   204896

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT anix-20220815.xsd EX-101.SCH 2950
3 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT anix-20220815_lab.xml EX-101.LAB 34240
4 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT anix-20220815_pre.xml EX-101.PRE 22353
6 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3621
Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Filer) CIK: 0000715446 (see all company filings)

EIN.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: 8-K | Act: 34 | File No.: 001-37492 | Film No.: 221172509
SIC: 2834 Pharmaceutical Preparations